DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,682,619 B2 Amodei Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,682,619 B2 Amodei Et Al USOO86826 19B2 (12) United States Patent (10) Patent No.: US 8,682,619 B2 Amodei et al. (45) Date of Patent: Mar. 25, 2014 (54) DEVICE INCLUDING ALTERED filed on Oct. 2, 2007, and a continuation-in-part of MICROORGANISMS, AND METHODS AND application No. 1 1/900,870, filed on Sep. 12, 2007, SYSTEMIS OF USE and a continuation-in-part of application No. (75) Inventors: Dario G. Amodei, Princeton, NJ (US); 11/900,776, filed on Sep. 12, 2007, and a Mahalaxmi Gita Bangera, Renton, WA continuation-in-part of application No. 1 1/900,773, (US); Xiaoyan Robert Bao, Cambridge, filed on Sep. 12, 2007, now Pat. No. 8,252,570, and a MA (US); Anna Bershteyn, Somerville, continuation-in-part of application No. 1 1/701,163, MA (US); Brett Bethke, Arlington, MA filed on Jan. 31, 2007, now Pat. No. 8,354.258, and a (US); Philip A. Eckhoff, Bellevue, WA continuation-in-part of application No. 1 1/452.019, (US); Kevin Michael Esvelt, filed on Jun. 12, 2006, and a continuation-in-part of Cambridge, MA (US); Kyle B. application No. 1 1/451,994, filed on Jun. 12, 2006, and Gustafson, Lausanne (CH); Edward K. a continuation-in-part of application No. 1 1/451,986, Y. Jung, Bellevue, WA (US); William filed on Jun. 12, 2006, now Pat. No. 8,053,220, and a Michael Kaminsky, Alexandria, VA continuation-in-part of application No. 1 1/389.268, (US); Jordin T. Kare, Seattle, WA (US); filed on Mar. 24, 2006, and a continuation-in-part of Lily Yvonne Kim, Brookline, MA (US); application No. 1 1/304,499, filed on Dec. 14, 2005, Eric C. Leuthardt, St. Louis, MO (US); now Pat. No. 8.278,094, and a continuation-in-part of Erez Lieberman, Cambridge, MA (US); application No. 1 1/304,492, filed on Dec. 14, 2005, Ankur Moitra, Cambridge, MA (US); now Pat. No. 7,855,062, and a continuation-in-part of Christopher Somogyi, Woodinville, WA application No. 1 1/304,486, filed on Dec. 14, 2005, (US); Clarence T. Tegreene, Bellevue, now Pat. No. 8,198,080. WA (US); Lowell L. Wood, Jr., Bellevue, WA (US); Jeremiah James (51) Int. C. Zartman, Montgomery, AL (US) GOIN 33/48 (2006.01) (73) Assignee: The Invention Science Fund I, LLC, GOIN3L/00 (2006.01) Bellevue, WA (US) G06F 17/50 (2006.01) (*) Notice: Subject to any disclaimer, the term of this G06F 9/00 (2011.01) patent is extended or adjusted under 35 (52) U.S. C. U.S.C. 154(b) by 402 days. CPC .................................. G06F 19/3468 (2013.01) (21) Appl. No.: 12/802,149 USPC .................................... 703/1702/19, 702/27 (22) Filed: May 28, 2010 (58) Field of Classification Search None (65) Prior Publication Data See application file for complete search history. US 2011 FOO28945A1 Feb. 3, 2011 (56) References Cited Related U.S. Application Data U.S. PATENT DOCUMENTS (63) Continuation-in-part of application No. 12/802,148, 4,352.581 A 10, 1982 Leuthold et al. filed on May 28, 2010, and a continuation-in-part of 4,627,853. A 12/1986 Campbell et al. application No. 12/806,637, filed on May 28, 2010, and a continuation-in-part of application No. (Continued) 127657,604, filed on Jan. 22, 2010, and a FOREIGN PATENT DOCUMENTS continuation-in-part of application No. 127657,605, filed on Jan. 22, 2010, and a continuation-in-part of WO WO95/24929 9, 1995 application No. 127657,606, filed on Jan. 22, 2010, and WO WO96,40947 12/1996 a continuation-in-part of application No. 127657,607, (Continued) filed on Jan. 22, 2010, and a continuation-in-part of application No. 127657,608, filed on Jan. 22, 2010, and OTHER PUBLICATIONS a continuation-in-part of application No. 127657,609, Auxotrophic, 2007, one page. The American Heritage Dictionary of filed on Jan. 22, 2010, and a continuation-in-part of the English Language. Retrieved online on Sep. 2, 2012 <<http:// application No. 12/462,114, filed on Jul. 28, 2009, now www.credoreference.com/entry/hmdictenglang/auxtotrophic). Pat. No. 8,551,750, and a continuation-in-part of application No. 11/975,605, filed on Oct. 18, 2007, (Continued) now Pat. No. 8,114,647, and a continuation-in-part of Primary Examiner — Russell S Negin application No. 11/974,750, filed on Oct. 15, 2007, now Pat. No. 8.304.220, and a continuation-in-part of (57) ABSTRACT application No. 11/974,852, filed on Oct. 15, 2007, Devices, methods, and systems are described for administra now Pat. No. 8.367,384, and a continuation-in-part of tion to at least one biological tissue of at least one device application No. 11/974,798, filedon Oct. 15, 2007, and including at least one altered microorganism. In an embodi a continuation-in-part of application No. 1 1/906,664, ment, the altered microorganism includes at least one nucleic filed on Oct. 2, 2007, and a continuation-in-part of acid construct encoding at least one therapeutic agent. application No. 1 1/906,581, filed on Oct. 2, 2007, and a continuation-in-part of application No. 1 1/906,580, 55 Claims, 36 Drawing Sheets US 8,682,619 B2 Page 2 (56) References Cited 2004/0229333 A1 11/2004 Bowlin et al. 2004/0241849 A1 12/2004 Kapat U.S. PATENT DOCUMENTS 2005, OO31643 A1 2/2005 Szalay et al. 2005/0101005 A1 5, 2005 Steidler 4,833,083 5, 1989 Saxena 2005, 0112133 A1 5, 2005 Druhe 4,837,151 6, 1989 Stocker 2005, 012401.0 A1 6/2005 Short et al. 5,017,373 5, 1991 Herrnstadt et al. 2005, 0131386 A1 6/2005 Freeman et al. 5,256,418 10, 1993 Kemp et al. 2005/O137626 A1 6/2005 Pastore et al. 5,316,940 5, 1994 Georgiou et al. 2005/0226856 A1 10, 2005 Ahlfors 5,324.294 6, 1994 Elia et al. 2005/0276788 A1 12/2005 Steidler et al. 5,578.485 11, 1996 Naughton et al. 2006/0030948 A1 2/2006 Manrique et al. 5,643,771 7, 1997 Stocker 2006, O121054 A1 6/2006 Sun et al. 5,663,063 9, 1997 Peoples et al. 2006/0177379 A1 8/2006 Asgari 5,762.965 6, 1998 Burnett et al. 2006/0207.168 A1 9/2006 Harper 5,804,563 9, 1998 Still et al. 2007/0026005 A1 2/2007 Sung et al. 5,820,873 10, 1998 Choi et al. 2007/0073385 A1 3/2007 Schaeffer et al. 5,823,993 10, 1998 Lemelson 2007/01 10723 A1 5/2007 Hans et al. 5,831,012 11, 1998 Nilsson et al. 2007/O122427 A1 5/2007 Hans et al. 5,843,781 12, 1998 Ballermann et al. 2007/0134216 A1 6/2007 Harlow et al. 5,858,318 1, 1999 Luo 2007/0134.222 A1 6/2007 Harlow et al. 5,876,452 3, 1999 Athanasiou et al. 2007/0134223 A1 6/2007 Harlow et al. 5,888,396 3, 1999 Perriello 2007/0134224 A1 6/2007 Harlow et al. 5,916,554 6, 1999 Dionne et al. 2007/0134225 A1 6/2007 Harlow et al. 5,916,870 6, 1999 Lee et al. 2007/0134345 A1 6/2007 Harlow et al. 5,928,635 7, 1999 Schmidt ....................... 424,85.1 2007/0134346 A1 6/2007 Harlow et al. 6,017,496 1, 2000 Nova et al. 2007. O184088 A1 8/2007 Jung et al. 6,066,343 5, 2000 Megeed et al. 2007/0213659 A1 9, 2007 Trovato et al. 6,100,388 8, 2000 Casas et al. 2007,0258901 A1 11/2007 Boschert et al. 6,126,936 10, 2000 Lanza et al. 2008/0044448 A1 2/2008 Harlow et al. 6,126,956 10, 2000 Grossman et al. 2008/0044900 A1 2/2008 Mooney et al. 6,200,347 3, 2001 Anderson et al. 2008/0050416 A1 2/2008 Harlow et al. 6,242,194 6, 2001 Kullen et al. 2008. O107686 A1 5, 2008 Mach 6,254,832 T/2001 Rainin et al. 2008/0253990 A1 10, 2008 Steidler et al. 6,416,754 T/2002 Brown et al. 2008/0254014 A1 10, 2008 Rottiers et al. 6,592,989 T/2003 Senna et al. 2008/0311 145 A1 12/2008 Campion et al. 6,605,286 8, 2003 Steidler et al. 2009/0041836 A1 2/2009 Boons et al. 6,610,529 8, 2003 Curtiss, III et al. 2009. O115603 A1 5, 2009 Tabe 6,646,867 11, 2003 Tuttle et al. 2009, O148408 A1 6/2009 Chang et al. 6,652,849 11, 2003 Brown et al. 2009/0202608 A1 8, 2009 Alessi et al. 6,670,427 12, 2003 Ulbricht et al. 2010, O152880 A1 6/2010 Boyden et al. 6,696,251 2, 2004 Wittrup et al. 2010/0272771 A1 10, 2010 Harlow et al. 6,709,269 3, 2004 Altshuler 6,767,928 T/2004 Murphy et al. FOREIGN PATENT DOCUMENTS 6,790,455 9, 2004 Chu et al. 6,797,522 9, 2004 Still et al. WO WO99,38453 8, 1999 6,852,511 2, 2005 Romano et al. WO WO99/4708O 9, 1999 6,875,356 4, 2005 Perriello WO WOOOOO177 1, 2000 7,001,359 2, 2006 Rogers WO WOOOf 66188 A3 11, 2000 7,220,418 5/2007 Hans et al. WO WOO1? 68135 A2 3, 2001 7,226,612 6, 2007 Sohier et al. WO WOO1,24690 A2 * 4, 2001 7,341,860 3, 2008 Curtiss, III et al.
Load more

Recommended publications
  • A Taxonomic Note on the Genus Lactobacillus
    Taxonomic Description template 1 A taxonomic note on the genus Lactobacillus: 2 Description of 23 novel genera, emended description 3 of the genus Lactobacillus Beijerinck 1901, and union 4 of Lactobacillaceae and Leuconostocaceae 5 Jinshui Zheng1, $, Stijn Wittouck2, $, Elisa Salvetti3, $, Charles M.A.P. Franz4, Hugh M.B. Harris5, Paola 6 Mattarelli6, Paul W. O’Toole5, Bruno Pot7, Peter Vandamme8, Jens Walter9, 10, Koichi Watanabe11, 12, 7 Sander Wuyts2, Giovanna E. Felis3, #*, Michael G. Gänzle9, 13#*, Sarah Lebeer2 # 8 '© [Jinshui Zheng, Stijn Wittouck, Elisa Salvetti, Charles M.A.P. Franz, Hugh M.B. Harris, Paola 9 Mattarelli, Paul W. O’Toole, Bruno Pot, Peter Vandamme, Jens Walter, Koichi Watanabe, Sander 10 Wuyts, Giovanna E. Felis, Michael G. Gänzle, Sarah Lebeer]. 11 The definitive peer reviewed, edited version of this article is published in International Journal of 12 Systematic and Evolutionary Microbiology, https://doi.org/10.1099/ijsem.0.004107 13 1Huazhong Agricultural University, State Key Laboratory of Agricultural Microbiology, Hubei Key 14 Laboratory of Agricultural Bioinformatics, Wuhan, Hubei, P.R. China. 15 2Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience 16 Engineering, University of Antwerp, Antwerp, Belgium 17 3 Dept. of Biotechnology, University of Verona, Verona, Italy 18 4 Max Rubner‐Institut, Department of Microbiology and Biotechnology, Kiel, Germany 19 5 School of Microbiology & APC Microbiome Ireland, University College Cork, Co. Cork, Ireland 20 6 University of Bologna, Dept. of Agricultural and Food Sciences, Bologna, Italy 21 7 Research Group of Industrial Microbiology and Food Biotechnology (IMDO), Vrije Universiteit 22 Brussel, Brussels, Belgium 23 8 Laboratory of Microbiology, Department of Biochemistry and Microbiology, Ghent University, Ghent, 24 Belgium 25 9 Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, Canada 26 10 Department of Biological Sciences, University of Alberta, Edmonton, Canada 27 11 National Taiwan University, Dept.
    [Show full text]
  • Harnessing the Power of Bacteria in Advancing Cancer Treatment
    International Journal of Molecular Sciences Review Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment Shruti S. Sawant, Suyash M. Patil, Vivek Gupta and Nitesh K. Kunda * Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Jamaica, NY 11439, USA; [email protected] (S.S.S.); [email protected] (S.M.P.); [email protected] (V.G.) * Correspondence: [email protected]; Tel.: +1-718-990-1632 Received: 20 September 2020; Accepted: 11 October 2020; Published: 14 October 2020 Abstract: Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and radiation and are often non-specific in action. The development of drug resistance and the inability of the drug to penetrate the tumor cells has been a major pitfall in current treatment. This has led to the investigation of alternative anti-tumor therapeutics possessing greater specificity and efficacy. There is a significant interest in exploring the use of microbes as potential anti-cancer medicines. The inherent tropism of the bacteria for hypoxic tumor environment and its ability to be genetically engineered as a vector for gene and drug therapy has led to the development of bacteria as a potential weapon against cancer. In this review, we will introduce bacterial anti-cancer therapy with an emphasis on the various mechanisms involved in tumor targeting and tumor suppression. The bacteriotherapy approaches in conjunction with the conventional cancer therapy can be effective in designing novel cancer therapies. We focus on the current progress achieved in bacterial cancer therapies that show potential in advancing existing cancer treatment options and help attain positive clinical outcomes with minimal systemic side-effects.
    [Show full text]
  • Molecular Analysis of Candidate Probiotic Effector Molecules of Lactobacillus Plantarum
    Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Daniela Maria Remus Thesis committee Promoter Prof. dr. Michiel Kleerebezem Professor of Bacterial Metagenomics Wageningen University Co-promoter Dr. Peter A. Bron Senior Scientist, NIZO food research BV, Ede Other members Prof. dr. Tjakko Abee, Wageningen University Prof. dr. Pascal Hols, University of Lovain (Lovain la Neuve), Belgium Dr. Philippe Langella, National Institute of Agricultural Research (INRA), Paris, France Prof. dr. Roland J. Siezen, Radboud University, Nijmegen This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Daniela Maria Remus Thesis submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Tuesday 09 October 2012 at 4 p.m. in the Aula. Daniela Maria Remus Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Ph.D. Thesis, Wageningen University, Wageningen, The Netherlands (2012) With references and summaries in English and Dutch. ISBN 978-94-6173-373-3 Summary Lactobacilli occupy diverse natural habitats, including dairy products and the mammalian gastrointestinal (GI) tract, and several Lactobacillus strains are marketed as probiotics that can interact with host cells in the GI tract by which they are proposed to beneficially influence the health status of their consumers. The discovery of probiotic effector molecules is instrumental to understand the exact modes of probiotic action, which is required for their controlled, safe, and purpose-directed application.
    [Show full text]
  • Plantaricin KW30
    The Molecular and Cellular Characterisation of the First Glycocin: Plantaricin KW30 Judith Stepper 2009 The Molecular and Cellular Characterisation of the First Glycocin: Plantaricin KW30 A thesis presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biochemistry at Massey University, Palmerston North, New Zealand Judith Stepper 2009 “What we know is a drop. What we don’t know is an ocean.” Isaac Newton (1643 – 1727) ABSTRACT Bacteriocins, typically secreted by Gram-positive and -negative bacteria, are ribosomally- synthesised antimicrobial peptides which inhibit the growth of competing bacteria. We have purified a 43 amino acid bacteriocin, plantaricin KW30 (PlnKW30) produced by Lactobacillus plantarum KW30, that has little amino acid sequence similarity to any other characterised bacteriocin. The gene encoding plnKW30 is in a cluster with the genes required for maturation and export of, and immunity to, the bacteriocin. This arrangement of genes is similar to the genomic context of bacteriocin genes in other lactic acid bacteria. The plnKW30 gene cluster comprises six genes encoding a glycosyltransferase, a proteolytic ABC-transporter, two putative thioredoxins, a response regulator and PlnKW30 itself. PlnKW30 was found to possess two unusual post-translational modifications: an O-glycosylated serine and an unprecedented S-glycosylation of the C-terminal cysteine. The modified serine is located on an eight residue loop that is tethered by a disulfide bridge. Both modifications have been identified as N-acetylglucosamines (GlcNAc), making PlnKW30 the first described class IV bacteriocin. A post-translational modification with S-linked GlcNAc is unprecedented in bacteriocins as well as in all genera.
    [Show full text]
  • The Bacteriostatic Diglycocylated Bacteriocin Glycocin F Targets A
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. The Bacteriostatic Diglycosylated Bacteriocin Glycocin F Targets a Sugar-Specific Transporter A thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University, Manawatu New Zealand Kelvin Ross Drower 2014 Dedicated to Nana and Pop Abstract The increasing prevalence of antibiotic-resistance bacteria is threatening to end the antibiotic era established following Alexander Fleming's discovery of penicillin in 1928. Over-prescription and misuse of broad-spectrum antibiotics has hastened the development and spread of antibiotic resistance. This, combined with a lack of research and development (R&D) of new antibiotics by major pharmaceutical companies, may lead to a widespread recurrence of 'incurable' bacterial diseases. However while commercial R&D of antibiotics has waned, much research has been carried out to characterise bacteriocins, ribosomally-synthesised antimicrobial polypeptides thought to be produced by virtually all prokaryotes. Although hundreds of bacteriocins have been identified and characterised, only a handful of their cognate receptors on susceptible cells have been identified. Glycocin F is a bacteriostatic diglycosylated 43-amino acid bacteriocin produced by the Gram-positive bacterium Lactobacillus plantarum KW30 that inhibits the growth of a broad range of bacteria. The mechanism of action of glycocin F is unknown, however evidence suggested that glycocin F binds to cells via a N-acetylglucosamine (GlcNAc) specific phosphoenolpyruvate:carbohydrate-phosphotransferase system (PTS) transporter, as had been shown for lactococcin A, lactococcin B and microcin E492 that target a mannose specific PTS transporter.
    [Show full text]
  • UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Interactions of Microbes in Communities Permalink https://escholarship.org/uc/item/2hg5h7k6 Author Sczesnak, Andrew Publication Date 2018 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Interactions of Microbes in Communities By Andrew Sczesnak A dissertation submitted in partial satisfaction of the requirements for the degree of Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Adam P. Arkin, Chair Professor Matthew Traxler Professor Michael Fischbach Fall 2018 Abstract Interactions of Microbes in Communities By Andrew Sczesnak Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering University of California, Berkeley Professor Adam P. Arkin, Chair Groups of microorganisms sharing an environment (microbial communities) are ubiquitous in nature. Microbial communities provide essential ecosystem services to other life on Earth by e.g., participating in global biogeochemical processes or interacting with a host’s immune system. Such microbes compete for scarce resources, modify an environment for their own purposes, actively war, and occasionally cooperate. Though numerous studies have surveyed the diversity of microbial life in different environments, few have determined the ways in which members of microbial communities interact with one another. Understanding the ways and means by which microbes interact is essential if we are to understand how microbial communities form, persist, and change over time. Knowledge of these processes will allow us to rationally design microbial communities to perform useful functions and predict how our actions might shift the balance of microbes in a community, and thus affect its function.
    [Show full text]
  • Probiotic Dairy Products Society of Dairy Technology Series
    Probiotic Dairy Products Society of Dairy Technology Series Series Editor: Adnan Y. Tamime The Society of Dairy Technology has joined with Wiley‐Blackwell to produce a series of technical dairy‐related handbooks providing an invaluable resource for all those involved in the dairy industry; from practitioners to technologists working in both tradi- tional and modern large‐scale dairy operations. Probiotic Dairy Products, 2nd Edition, ISBN 9781119214106 by Adnan Y. Tamime and Linda V. Thomas (Editors) Microbial Toxins in Dairy Products, ISBN 9781118756430 by Adnan Y. Tamime (Editor) Biofilms in the Dairy Industry, ISBN 9781118876213 by Koon Hoong Teh, Steve Flint, John Brooks, and Geoff Knight (Editors) Milk and Dairy Products as Functional Foods, ISBN 9781444336832 by Ara Kanekanian (Editor) Membrane Processing: Dairy and Beverage Applications, ISBN 9781444333374 by Adnan Y. Tamime (Editor) Processed Cheese and Analogues, ISBN 9781405186421 by Adnan Y. Tamime (Editor) Technology of Cheesemaking, 2nd Edition, ISBN 9781405182980 by Barry A. Law and Adnan Y. Tamime (Editors) Dairy Fats and Related Products, ISBN 9781405150903 by Adnan Y. Tamime (Editor) Dairy Powders and Concentrated Products, ISBN 9781405157643 by Adnan Y. Tamime (Editor) Milk Processing and Quality Management, ISBN 9781405145305 by Adnan Y. Tamime (Editor) Cleaning‐in‐Place: Dairy, Food and Beverage Operations, 3rd Edition, ISBN 9781405155038 by Adnan Y. Tamime (Editor) Structure of Dairy Products, ISBN 9781405129756 by Adnan Y. Tamime (Editor) Brined Cheeses, ISBN 9781405124607 by Adnan Y. Tamime (Editor) Fermented Milks, ISBN 9780632064588 by Adnan Y. Tamime (Editor) Probiotic Dairy Products, ISBN 9781405121248 by Adnan Y. Tamime (Editor) Probiotic Dairy Products Second Edition Edited by Adnan Y.
    [Show full text]
  • Produced by Bacillus Amylo- Liquefaciens Isolated From
    RESEARCH ARTICLE INTERNATIONAL MICROBIOLOGY (2006) 9:111-118 www.im.microbios.org Márcia P. Lisboa1 Characterization of a Diego Bonatto2 Delmar Bizani1 bacteriocin-like substance João A.P. Henriques3 produced by Bacillus amylo- Adriano Brandelli1* liquefaciens isolated from 1Department of Science Food, the Brazilian Atlantic forest ICTA, Federal University of Rio Grande do Sul, Porto Alegre, Brazil 2Biotechnology Institute, University of Caxias do Sul, Brazil 3Biotechnology Center, Federal University of Rio Grande do Sul, Summary. A Bacillus strain producing a bacteriocin-like substance was charac- Porto Alegre, Brazil terized by biochemical profiling and 16S rDNA sequencing. Phylogenetic analysis indicated that the strain has high sequence similarity with Bacillus amyloliquefa- ciens. The antimicrobial substance was inhibitory to pathogenic and food-spoilage bacteria, such as Listeria monocytogenes, Bacillus cereus, Serratia marcescens, and Pasteurella haemolytica. It was stable over a wide temperature range, but lost activity when the temperature reached 121°C/15 min. Maximum activity was observed at acidic and neutral pH values, but not at alkaline pH. The antimicrobial Received 18 February 2006 substance was sensitive to the proteolytic action of trypsin, papain, proteinase K, Accepted 17 May 2006 and pronase E. Except for iturins, other antimicrobial peptides have not been des- *Corresponding author: cribed for B. amyloliquefaciens. The identification of a bacteriocin-like inhibitory A. Brandelli substance active against L. monocytogenes addresses an important aspect of food ICTA-UFRGS protection. [Int Microbiol 2006; 9(2):111-118] Av. Bento Gonçalves 9500 91501-970 Porto Alegre, Brazil Tel. +55-5133166249 Fax +55-5133167048 Key words: Bacillus amyloliquefaciens · antimicrobial activity · bacteriocin · E-mail: [email protected] bioactive peptide many attempts are being made to incorporate bacteriocins Introduction into processes and products [25].
    [Show full text]
  • Marmoset Models Commonly Used in Biomedical Research
    Comparative Medicine Vol 53, No 4 Copyright 2003 August 2003 by the American Association for Laboratory Animal Science Pages 383-392 Overview Marmoset Models Commonly Used in Biomedical Research Keith Mansfield, DVM The common marmoset (Callithrix jacchus ) is a small, nonendangered New World primate that is native to Brazil and has been used extensively in biomedical research. Historically the common marmoset has been used in neuro- science, reproductive biology, infectious disease, and behavioral research. Recently, the species has been used in- creasingly in drug development and safety assessment. Advantages relate to size, cost, husbandry, and biosafety issues as well as unique physiologic differences that may be used in model development. Availability and ease of breeding in captivity suggest that they may represent an alternative species to more traditional nonhuman pri- mates. The marmoset models commonly used in biomedical research are presented, with emphasis on those that may provide an alternative to traditional nonhuman primate species. In contrast to many other laboratory animal species, use of nonhuman primate species. nonhuman primates has increased in recent years and there Common marmosets represent an attractive alternative non- currently exists a substantial shortage of such animals for use human primate species for a variety of reasons. These small in biomedical research. The national supply of macaque mon- hardy animals breed well in captivity, with reproductive effi- keys has been unable to meet the current or projected demands ciency that may exceed 150% (number of live born per year/ of the research community. Although efforts are underway to number of breeding females). Furthermore, sexual maturity is increase domestic production and to identify alternative foreign reached by 18 months of age, allowing rapid expansion of exist- sources, this will unlikely alter short-term availability.
    [Show full text]
  • GRAS Notice 685, Lactobacillus Plantarum Strain 299V
    GRAS Notice (GRN) No. 685 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm ORIGINAL SUBMISSION 1701 Pennsylvania Avenue, NW Attomeys at Law in Suite 700 Chicago Quoties/ Bmdy u.r Washington, District of Columbia 20006-5805 Indianapolis 202.372.9600 Madison Fax 202.372.9599 Milwaukee www.quarles.com Naples Phoenix Scottsdale Tampa Tucson Washington, D.C. Writer's Direct Dial: 202-372-9529 E-Mail: [email protected] December 20,2016 BY Hand Delivery United States Food and Drug Administration Center for Food Safety and Applied Nutrition Office ofFood Additive Safety HFS-200 5001 Campus Drive College Park, MD 20740 Re: GRAS Notification for Lactobacillus plantarum Strain 299v Dear Dr. Anderson: Enclosed is a copy of a GRAS notification submitted on behalfofProbi AB, of Lund, Sweden ("Probi") through its Agent Mark Yacura ofthe law firm Quarles & Brady LLP in accordance with the requirements of21 C.F.R. Part 170, Subpart E. If you have any questions or concerns regarding these minutes, please contact me at (202) 372-9529 or at [email protected]. Sincerely, (b) (6) fR1[E~[EG~[EfQJ DEC 2 1 2016 OFFICE OF FOOD ADDITIVE SAFETY Generally Recognized as Safe (GRAS) Determination for the Use of Lactobacillus plantarum Strain 299v in Conventional Foods Submitted by ProbiAB Lund, Sweden Submitted to United States Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food Additive Safety HFS-200 5001 Campus Drive College Park, MD 20740 Prepared by ProbiAB and JHeimbach LLC Port Royal, Virginia December 2016 GRAS Determination for 1 JHEJMBACH LLC Lactobacillus plantarum 299v Table of Contents Part 1 - Signed Statements and Certification............................................................................
    [Show full text]
  • Non-Canonical Functions of the Bacterial Sos Response
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2019 Non-Canonical Functions Of The aB cterial Sos Response Amanda Samuels University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Microbiology Commons Recommended Citation Samuels, Amanda, "Non-Canonical Functions Of The aB cterial Sos Response" (2019). Publicly Accessible Penn Dissertations. 3253. https://repository.upenn.edu/edissertations/3253 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3253 For more information, please contact [email protected]. Non-Canonical Functions Of The aB cterial Sos Response Abstract DNA damage is a pervasive environmental threat, as such, most bacteria encode a network of genes called the SOS response that is poised to combat genotoxic stress. In the absence of DNA damage, the SOS response is repressed by LexA, a repressor-protease. In the presence of DNA damage, LexA undergoes a self-cleavage reaction relieving repression of SOS-controlled effector genes that promote bacterial survival. However, depending on the bacterial species, the SOS response has an expanded role beyond DNA repair, regulating genes involved in mutagenesis, virulence, persistence, and inter-species competition. Despite a plethora of research describing the significant consequences of the SOS response, it remains unknown what physiologic environments induce and require the SOS response for bacterial survival. In Chapter 2, we utilize a commensal E. coli strain, MP1, and established that the SOS response is critical for sustained colonization of the murine gut. Significantly, in evaluating the origin of the genotoxic stress, we found that the SOS response was nonessential for successful colonization in the absence of the endogenous gut microbiome, suggesting that competing microbes might be the source of genotoxic stress.
    [Show full text]
  • A Taxonomic Note on the Genus Lactobacillus
    TAXONOMIC DESCRIPTION Zheng et al., Int. J. Syst. Evol. Microbiol. DOI 10.1099/ijsem.0.004107 A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae Jinshui Zheng1†, Stijn Wittouck2†, Elisa Salvetti3†, Charles M.A.P. Franz4, Hugh M.B. Harris5, Paola Mattarelli6, Paul W. O’Toole5, Bruno Pot7, Peter Vandamme8, Jens Walter9,10, Koichi Watanabe11,12, Sander Wuyts2, Giovanna E. Felis3,*,†, Michael G. Gänzle9,13,*,† and Sarah Lebeer2† Abstract The genus Lactobacillus comprises 261 species (at March 2020) that are extremely diverse at phenotypic, ecological and gen- otypic levels. This study evaluated the taxonomy of Lactobacillaceae and Leuconostocaceae on the basis of whole genome sequences. Parameters that were evaluated included core genome phylogeny, (conserved) pairwise average amino acid identity, clade- specific signature genes, physiological criteria and the ecology of the organisms. Based on this polyphasic approach, we propose reclassification of the genus Lactobacillus into 25 genera including the emended genus Lactobacillus, which includes host- adapted organisms that have been referred to as the Lactobacillus delbrueckii group, Paralactobacillus and 23 novel genera for which the names Holzapfelia, Amylolactobacillus, Bombilactobacillus, Companilactobacillus, Lapidilactobacillus, Agrilactobacil- lus, Schleiferilactobacillus, Loigolactobacilus, Lacticaseibacillus, Latilactobacillus, Dellaglioa,
    [Show full text]